In the IPASS study comparing gefitinib with carboplatin and paclitaxel as the first-line therapy in Asian patients, NSCLC patients with EGFR mutation had a higher response rate than patients without EGFR mutations when they received carboplatin and paclitaxel. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.